Introduction
Kimia Farma is one of the leading pharmaceutical companies in Indonesia. Every year, the company publishes an annual report that provides insights into its operations and financial performance. In this article, we will take a closer look at the Kimia Farma 2018 annual report.
Overview of Kimia Farma 2018
The annual report highlights that Kimia Farma had a successful year in 2018. The company recorded a revenue of IDR 10.4 trillion and a net profit of IDR 450 billion. This was a significant improvement from its 2017 performance, where the company recorded a net profit of IDR 187 billion.
Financial Performance
The report provides a detailed breakdown of Kimia Farma’s financial performance. The company’s revenue was primarily driven by its pharmaceutical and healthcare services segments. The pharmaceutical segment recorded a revenue of IDR 8.8 trillion, while the healthcare services segment recorded a revenue of IDR 1.5 trillion.
The report also highlights that the company’s gross profit margin improved from 24.2% in 2017 to 28.3% in 2018. This was due to a better product mix and improved operational efficiency.
Business Highlights
The annual report also provides an overview of Kimia Farma’s business highlights in 2018. The company launched several new products, including generic drugs and over-the-counter medicines. It also expanded its healthcare services segment by opening new clinics and pharmacies across Indonesia.
In addition, the company signed several partnerships and collaborations with other companies in the healthcare industry. This included a joint venture with a Malaysian company to manufacture and distribute halal vaccines.
Corporate Social Responsibility
Kimia Farma is committed to making a positive impact on society. The annual report highlights the company’s corporate social responsibility initiatives in 2018. This included providing free healthcare services to underprivileged communities and supporting disaster relief efforts.
Conclusion
The Kimia Farma 2018 annual report shows that the company had a successful year. Its financial performance improved significantly, and it made strides in expanding its business and contributing to society. Overall, the annual report provides valuable insights into Kimia Farma’s operations, and it is a useful resource for investors, stakeholders, and anyone interested in the pharmaceutical industry in Indonesia.